


Reintroduction of WPV1 in an IPV vaccinated population

Prof. Itamar Grotto, Director, Public Health Services Dr. Lester Shulman, Head of National Environmental Virology Laboratory Dr. Boaz Lev, Associate Director General, Israel Ministry of Health

Poliomyelitis

Number of cases and rates per 100,000: 1951-2010



Number of cases



IPV vaccination coverage

- Israel ~ 95%
- Southern District ~ 92%
- Arabs ~ 97%
- Bedouins in Southern district ~ 90%

Sero-prevalence study: 98.2% positive



Supplementary Environmental Surveillance

- Routine monthly sewage surveillance
 - -8-10 sites since 1989
 - -30% 40% of entire population
 - -Measure viral loads



The initial event: Observation of a Dramatic rise in plaques

Location	Feb	Mar
Beer-Sheva	2, 1, 0, 0 0.4/ml	10, 10, 6, 3 3.7/ml
Rahat	1, 0, 0, 0 0.1/ml	57, 50, 48, 48 25.4/ml

Plaque assay of concentrated sewage on L20B



The WPV in Israel

- Identify viruses based on sequence
 - May 29th non-Sabin type 1 poliovirus
 - CDC and WHO closest match to WPV1 SOAS from Pakistan 2012 and Egypt (Dec 2012)
 - Clade R3





WPV circulation in Israel and The PA

- 350 samples Israel and PA; 109 SOAS positive
- High viral load: Parts of Southern District, mainly in Bedouin settlements
- Low viral load: Four locations in Central Israel
- "Anecdotal" virus identification: Four other locations in Central Israel; three location in the PA



Public Health Response



1st Stage Response: June–July 2013: IPV phase

- Nationwide active IPV catch-up: with focus on South
 Achieving >98% coverage among children
- Rahat : Single dose IPV for adults
- National hygiene campaign hygiene
- Intensified environmental surveillance (>50 sites)
- Intensified AFP and aseptic meningitis surveillance
- Stool survey Southern district (July 2013)
- Communication with health professionals and public





Stool survey (CDC and CVL, n=2,203)

- Identified reservoir
 - Bedouin children < 9 years old</p>
 - Point prevalence: 4.2%
 - Jewish children < 9 years old</p>
 - Point prevalence: 0.6%
 - 48/50 excretors among IPV-only vaccinated children
 - Distribution of excretors consistent with environmental surveillance "hot spots"



2nd Stage Response Aug 5th & 18th bOPV

- Single bOPV dose if previous IPV dose.
- Aug 5 Southern Israel– 180,000 Children <10 yrs
 - SIA bOPV
 - 86% by Sept 26th
- Aug 18 all other children- total of 1.2 Million
 - SIA bOPV
 - 70% by Sept 25th




Challenges of OPV SIA

- SIA in an IPV-only country with no clinical polio
- Identify the target population for SIA
- Reach consensus in the medical community
- Risk communication to general public:
 - "Traditional" media
 - "New" media: internet and social networks
 - Community leaders
- Appeal to Supreme Court against vaccination campaign
- "halo" effect on other routine vaccines
- Compliance




Rahat – WPV1 kinetics (high viral load)





Kiryat-Gat– WPV1 kinetics (low viral load)





Next step(s)

Additional round(s) of bOPV?

 Reexamination of childhood vaccination schedules: re-include tOPV or bOPV with IPV?



Conclusions

- Evidence: Introduction and sustained transmission of WPV1 in a highly vaccinated population
- Evidence-based national public health response
 - Time needed to acquire data and public trust
 - Consultation with external experts WHO and CDC
- Continuous Environmental surveillance crucial for Early detection and monitoring intervention





Future International Considerations

Applying research evidence from Israel's event for polio endgame strategy

 We are open to suggestions to any additional studies that would help toward understanding this type of event



Thank you:

WHO CDC NIBSC RIVM






Immune status of population (during event)

- Neutralizing antibodies to type 1poliovirus (>1:8)
 - 98.2%
- Neutralization of SOAS vs IPV Type 1
 - 3 fold less, but all STILL neutralize SOAS
 - convenient serum samples
 - low and mid range titers
 - Mahoney GMT = 41 SOAS GMT = 13



Environmental surveillance sites

- Include additional surveillance sites (n>50)
- Increase frequency of testing from monthly to weekly
- Subdivide sampling sites (upstream branches)



pled at specific week, positive at least once